EUVIMEDEUVIMED entdecken
Crossref

Validated GC–MS and LC–MS/MS Methods for ICH M7–Based Quantification of Alkyl Mesylate and Azido Genotoxic Impurities in Pharmaceutical Products

Neşet Neşetoğlu iD, Durişehvar Özer Ünal iD

Biomedical Chromatography · 2026

DOI: 10.1002/bmc.70357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Neşet Neşetoğlu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Drug Contamination, Liquid Chromatography-Mass Spectrometry, Tandem Mass Spectrometry, Gas Chromatography-Mass Spectrometry. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genotoxic impurities (GTIs) in pharmaceutical products represent a critical safety concern because they can induce DNA damage and may lead to mutagenic and carcinogenic effects even at trace concentrations. Consequently, regulatory authorities such as EMA, FDA, and ICH require a risk‐based and impurity‐specific control strategy, as defined in ICH M7, for active pharmaceutical ingredients (APIs) and finished dosage forms. Due to their structural and physicochemical diversity, GTIs cannot be adequately monitored using a single analytical technique, and method selection must be tailored to the characteristics of each impurity. In this study, impurity‐specific analytical methods were developed and validated to demonstrate the practical application of this regulatory approach in different pharmaceutical matrices. GC–MS method was optimized for the determination of volatile alkylating agents, namely methyl, ethyl, and isopropyl methanesulfonate in imatinib mesylate API. LC–MS/MS method was established for the quantification of 5‐(4′‐(azidomethyl)‐[1,1′‐biphenyl]‐2‐yl)‐1H‐tetrazole, a polar and thermolabile azido impurity in valsartan formulations. Both methods were validated in accordance with ICH Q2(R1) guidelines, demonstrating excellent specificity, linearity ( R 2 > 0.999), accuracy, and precision, with detection limits sufficient to meet regulatory requirements. Application to commercial products confirmed the robustness of methods and their suitability for routine quality control supporting effective GTI risk management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ContaminationLiquid Chromatography-Mass SpectrometryTandem Mass SpectrometryGas Chromatography-Mass SpectrometryMutagensMesylatesReproducibility of ResultsLinear ModelsLimit of DetectionBulk Drugs

Stichwörter der Autor:innen

AZBTGC–MSLC–MS/MSalkyl mesylatesgenotoxic impuritiespharmaceutical safety

Substanzen

MutagensBulk DrugsMesylates

Autor:innen und Institutionen

  • Department of Analytical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
  • Drug Application and Research Center, Istanbul University, Istanbul, Turkey.

ORCID-Profile: Neşet Neşetoğlu, Durişehvar Özer Ünal

Zitieren

APA

Neşetoğlu, N., & Ünal, D. Ö. (2026). Validated GC–MS and LC–MS/MS Methods for ICH M7–Based Quantification of Alkyl Mesylate and Azido Genotoxic Impurities in Pharmaceutical Products. Biomedical Chromatography. https://doi.org/10.1002/bmc.70357

Vancouver

Neşetoğlu N, Ünal DÖ. Validated GC–MS and LC–MS/MS Methods for ICH M7–Based Quantification of Alkyl Mesylate and Azido Genotoxic Impurities in Pharmaceutical Products. Biomedical Chromatography. 2026. doi:10.1002/bmc.70357

BibTeX
@article{Neetolu2026,
  author = {Neşetoğlu, Neşet and Ünal, Durişehvar Özer},
  title = {Validated GC–MS and LC–MS/MS Methods for ICH M7–Based Quantification of Alkyl Mesylate and Azido Genotoxic Impurities in Pharmaceutical Products},
  journal = {Biomedical Chromatography},
  year = {2026},
  doi = {10.1002/bmc.70357}
}
Kostenlos starten →